Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS

Journal of Genetics

Volumn 89, Issue 1, 2010, Pages 109-116

  Chatterjee, Koushik ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

AIDS; genetics; HIV; polymorphism; progression

Indexed keywords

CELL SURFACE RECEPTOR; HISTOCOMPATIBILITY ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PHYSIOLOGY; REVIEW; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS; HIV-1; HUMANS; RECEPTORS, CELL SURFACE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77955696250     PISSN: 00221333     EISSN: 09737731     Source Type: Journal    
DOI: 10.1007/s12041-010-0003-4     Document Type: Review

References (103)

1. Alkhatib G., Combadiere C., Broder C. C., Feng Y., Kennedy P. E., Murphy P. M. and Berger E. A. 1996 CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science272, 1955-1958.
2. An P., Nelson G. W., Wang L., Donfield S., Goedert J. J., Phair J. et al. 2002 Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc. Natl. Acad. Sci. USA99, 10002-10007.
3. An P., Bleiber G., Duggal P., Nelson G., May M., Mangeat B. et al. 2004 APOBEC3G genetic variants and their influence on the progression to AIDS. J. Virol. 78, 11070-11076.
4. Arenzana-Seisdedos F., Virelizier J. L., Rousset D., Clark-Lewis I., Loetscher P., Moser B. and Baggiolini M. 1996 HIV blocked by chemokine antagonist. Nature383, 400.
5. Biron C. A. and Brossay L. 2001 NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13, 458-464.
6. Bleiber G., May M., Martinez R., Meylan P., Ott J., Beckmann J. S. and Telenti A. 2005 Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants in-fluencing disease progression. J. Virol. 79, 12674-12680.
7. Bleul C. C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J. and Springer T. A. 1996 The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature382, 829-833.
8. Bleul C. C., Wu L., Hoxie J. A., Springer T. A. and Mackay C. R. 1997 The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA94, 1925-1930.
9. Bochud P. Y., Hersberger M., Taffe P., Bochud M., Stein C. M., Rodrigues S. D. et al. 2007 Polymorphisms in toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS21, 441-446.
10. Brennan F. M. and Feldmann M. 1996 Cytokines in autoimmunity. Curr. Opin. Immunol. 8, 872-877.
11. Brinkman B. M., Keet I. P., Miedema F., Verweij C. L. and Klein M. R. 1997 Polymorphisms within the human tumor necrosis factoralpha promoter region in human immunodeficiency virus type 1-seropositive persons. J. Infect. Dis. 175, 188-190.
12. Carrington M. and O'Brien S. J. 2003 The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535-551.
13. Carrington M., Nelson G. W., Martin M. P., Kissner T., Vlahov D., Goedert J. J. et al. 1999 HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science283, 1748-1752.
14. Carrington M., Nelson G. and O'Brien S. J. 2001 Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol. Lett. 79, 131-140.
15. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D. et al. 1996 The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell85, 1135-1148.
16. Cohen O. J., Paolucci S., Bende S. M., Daucher M., Moriuchi H., Moriuchi M. et al. 1998 CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32. J. Virol. 72, 6215-6217.
17. Combadiere C., Salzwedel K., Smith E. D., Tiffany H. L., Berger E. A. and Murphy P. M. 1998 Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J. Biol. Chem. 273, 23799-23804.
18. Crawley E., Kay R., Sillibourne J., Patel P., Hutchinson I. and Woo P. 1999 Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 42, 1101-1108.
19. D'Alfonso S. and Richiardi P. M. 1994 A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics39, 150-154.
20. D'Andrea A., Chang C., Franz-Bacon K., McClanahan T., Phillips J. H. and Lanier L. L. 1995 Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J. Immunol. 155, 2306-2310.
21. Dean M., Carrington M., Winkler C., Huttley G. A., Smith M. W., Allikmets R. et al. 1996 Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, Multicenter hemophilia cohort study, San Francisco city cohort, ALIVE Study. Science273, 1856-1862.
22. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M. et al. 1996 Identification of a major co-receptor for primary isolates of HIV-1. Nature381, 661-666.
23. Diop G., Hirtzig T., Do H., Coulonges C., Vasilescu A., Labib T. et al. 2006 Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed. Pharmacother. 60, 569-577.
24. Doherty P. C. and Zinkernagel R. M. 1975 Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature256, 50-52.
25. Doranz B. J., Rucker J., Yi Y., Smyth R. J., Samson M., Peiper S. C. et al. 1996 A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell85, 1149-1158.
26. Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A. et al. 1996 HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature381, 667-673.
27. Faure S., Meyer L., Costagliola D., Vaneensberghe C., Genin E., Autran B. et al. 2000 Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science287, 2274-2277.
28. Fellay J., Shianna K. V., Ge D., Colombo S., Ledergerber B., Weale M. et al. 2007 A whole-genome association study of major determinants for host control of HIV-1. Science317, 944-947.
29. Feng Y., Broder C. C., Kennedy P. E. and Berger E. A. 1996 HIV-1 entry cofactor: functional cDNA cloning of a seventransmembrane, G protein-coupled receptor. Science272, 872-877.
30. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M. and O'Garra A. 1991 IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815-3822.
31. Flores-Villanueva P. O., Yunis E. J., Delgado J. C., Vittinghoff E., Buchbinder S., Leung J. Y. et al. 2001 Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. USA98, 5140-5145.
32. Forthal D. N., Landucci G., Bream J., Jacobson L. P., Phan T. B. and Montoya B. 2007 FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179, 7916-7923.
33. Gao X., Nelson G. W., Karacki P., Martin M. P., Phair J., Kaslow R. et al. 2001 Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344, 1668-1675.
34. Gao X., Bashirova A., Iversen A. K., Phair J., Goedert J. J., Buchbinder S. et al. 2005 AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med11, 1290-1292.
35. Garred P., Madsen H. O., Balslev U., Hofmann B., Pedersen C., Gerstoft J. and Svejgaard A. 1997 Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet349, 236-240.
36. Goulder P. J., Bunce M., Krausa P., McIntyre K., Crowley S., Morgan B. et al. 1996 Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res. Hum. Retroviruses12, 1691-1698.
37. Goulder P. J., Phillips R. E., Colbert R. A., McAdam S., Ogg G., Nowak M. A. et al. 1997 Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212-217.
38. Hamann A., Mantzoros C., Vidal-Puig A. and Flier J. S. 1995 Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem. Biophys. Res. Commun. 211, 833-839.
39. Han X., Becker K., Degen H. J., Jablonowski H. and Strohmeyer G. 1996 Synergistic stimulatory effects of tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type 1 and on apoptosis of HIV-1-infected host cells. Eur. J. Clin. Invest. 26, 286-292.
40. Harris R. S., Bishop K. N., Sheehy A. M., Craig H. M., Petersen-Mahrt S. K., Watt I. N. et al. 2003 DNA deamination mediates innate immunity to retroviral infection. Cell113, 803-809.
41. He J., Chen Y., Farzan M., Choe H., Ohagen A., Gartner S. et al. 1997 CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature385, 645-649.
42. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J. and Navaratnam N. 2002 An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics79, 285-296.
43. Just J. J. 1995 Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: a review of the literature examining associations with HLA [corrected]. Hum. Immunol. 44, 156-169.
44. Kaur G. and Mehra N. 2009 Genetic determinants of HIV-1 infection and progression to AIDS: susceptibility to HIV infection. Tissue Antigens73, 289-301.
45. Khoo S. H., Pepper L., Snowden N., Hajeer A. H., Vallely P., Wilkins E. G. et al. 1997 Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS11, 423-428.
46. Kim S. H., Cohen B., Novick D. and Rubinstein M. 1997 Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene196, 279-286.
47. Knuchel M. C., Spira T. J., Neumann A. U., Xiao L., Rudolph D. L., Phair J. et al. 1998 Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. AIDS Res. Hum. Retroviruses14, 305-309.
48. Kollmann T. R., Pettoello-Mantovani M., Katopodis N. F., Hachamovitch M., Rubinstein A., Kim A. and Goldstein H. 1996 Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc. Natl. Acad. Sci. USA93, 3126-3131.
49. Kostrikis L. G., Huang Y., Moore J. P., Wolinsky S. M., Zhang L., Guo Y. et al. 1998 A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4, 350-353.
50. Kumar V., Prakash O., Manpreet S., Sumedh G. and Medhi B. 2006 Genetic basis of HIV-1 resistance and susceptibility: an approach to understand correlation between human genes and HIV-1 infection. Indian J. Exp. Biol. 44, 683-692.
51. Lecossier D., Bouchonnet F., Clavel F. and Hance A. J. 2003 Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science300, 1112.
52. Libert F., Cochaux P., Beckman G., Samson M., Aksenova M., Cao A. et al. 1998 The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum. Mol. Genet. 7, 399-406.
53. Lipscombe R. J., Sumiya M., Hill A. V., Lau Y. L., Levinsky R. J., Summerfield J. A. and Turner M. W. 1992 High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum. Mol. Genet. 1, 709-715.
54. Liu R., Paxton W. A., Choe S., Ceradini D., Martin S. R., Horuk R. et al. 1996 Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell86, 367-377.
55. Liu H., Chao D., Nakayama E. E., Taguchi H., Goto M., Xin X. et al. 1999 Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. USA96, 4581-4585.
56. Maas J., de Roda Husman A. M., Brouwer M., Krol A., Coutinho R., Keet I. et al. 1998 Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study. AIDS12, 2275-2280.
57. MacGinnitie A. J., Anant S. and Davidson N. O. 1995 Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J. Biol. Chem. 270, 14768-14775.
58. Madsen H. O., Garred P., Kurtzhals J. A., Lamm L. U., Ryder L. P., Thiel S. and Svejgaard A. 1994 A new frequent allele is the missing link in the structural polymorphism of the human mannanbinding protein. Immunogenetics40, 37-44.
59. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L. and Trono D. 2003 Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature424, 99-103.
60. Martin M. P., Dean M., Smith M. W., Winkler C., Gerrard B., Michael N. L. et al. 1998 Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science282, 1907-1911.
61. Martin M. P., Gao X., Lee J. H., Nelson G. W., Detels R., Goedert J. J. et al. 2002 Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31, 429-434.
62. Martin M. P., Qi Y., Gao X., Yamada E., Martin J. N., Pereyra F. et al. 2007 Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39, 733-740.
63. Martinson J. J., Chapman N. H., Rees D. C., Liu Y. T. and Clegg J. B. 1997 Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16, 100-103.
64. McDermott D. H., Zimmerman P. A., Guignard F., Kleeberger C. A., Leitman S. F. and Murphy P. M. 1998 CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet352, 866-870.
65. McDermott D. H., Beecroft M. J., Kleeberger C. A., Al-Sharif F. M., Ollier W. E., Zimmerman P. A. et al. 2000 Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS14, 2671-2678.
66. Michael N. L. 1999 Host genetic influences on HIV-1 pathogenesis. Curr. Opin. Immunol. 11, 466-474.
67. Michael N. L., Louie L. G., Rohrbaugh A. L., Schultz K. A., Dayhoff D. E., Wang C. E. and Sheppard H. W. 1997 The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat. Med. 3, 1160-1162.
68. Migueles S. A., Sabbaghian M. S., Shupert W. L., Bettinotti M. P., Marincola F. M., Martino L. et al. 2000 HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA97, 2709-2714.
69. Naif H. M., Li S., Ho-Shon M., Mathijs J. M., Williamson P. and Cunningham A. L. 1997 The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication. J. Immunol. 158, 501-511.
70. O'Connor D. H., Allen T. M., Vogel T. U., Jing P., DeSouza I. P., Dodds E. et al. 2002 Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8, 493-499.
71. Pastinen T., Liitsola K., Niini P., Salminen M. and Syvanen A. C. 1998 Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. AIDS Res. Hum. Retroviruses14, 695-698.
72. Paxton W. A., Martin S. R., Tse D., O'Brien T. R., Skurnick J., Van-Devanter N. L. et al. 1996 Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat. Med. 2, 412-417.
73. Phillips R. E., Rowland-Jones S., Nixon D. F., Gotch F. M., Edwards J. P., Ogunlesi A. O. et al. 1991 Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature354, 453-459.
74. Potts W. K. and Slev P. R. 1995 Pathogen-based models favoring MHC genetic diversity. Immunol. Rev. 143, 181-197.
75. Qi Y., Martin M. P., Gao X., Jacobson L., Goedert J. J., Buchbinder S. et al. 2006 KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2, e79.
76. Quillent C., Oberlin E., Braun J., Rousset D., Gonzalez-Canali G., Metais P. et al. 1998 HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet351, 14-18.
77. Ravetch J. V. and Bolland S. 2001 IgG Fc receptors. Annu. Rev. Immunol. 19, 275-290.
78. Reeves J. D., McKnight A., Potempa S., Simmons G., Gray P. W., Power C. A. et al. 1997 CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology231, 130-134.
79. Risma K. A., Wang N., Andrews R. P., Cunningham C. M., Ericksen M. B., Bernstein J. A. et al. 2002 V75R576 IL-4 receptor alpha is associated with allergic asthma and enhanced IL-4 receptor function. J. Immunol. 169, 1604-1610.
80. Rosenwasser L. J. and Borish L. 1997 Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am. J. Respir. Crit. Care Med. 156, S152-S155.
81. Rucker J., Edinger A. L., Sharron M., Samson M., Lee B., Berson J. F. et al. 1997 Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 71, 8999-9007.
82. Samson M., Libert F., Doranz B. J., Rucker J., Liesnard C., Farber C. M. et al. 1996 Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature382, 722-725.
83. Schols D. and De C. E. 1996 Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. J. Virol. 70, 4953-4960.
84. Sen G. C. 2001 Viruses and interferons. Annu. Rev. Microbiol. 55, 255-281.
85. Shiga H., Shioda T., Tomiyama H., Takamiya Y., Oka S., Kimura S. et al. 1996 Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS10, 1075-1083.
86. Smith M. W., Dean M., Carrington M., Winkler C., Huttley G. A., Lomb D. A. et al. 1997 Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia growth and development study (HGDS), multicenter AIDS cohort study (MACS), multicenter hemophilia cohort study (MHCS), San Francisco city cohort (SFCC), ALIVE study. Science277, 959-965.
87. Soriano A., Lozano F., Oliva H., Garcia F., Nomdedeu M., De Lazzari E. et al. 2005 Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics57, 644-654.
88. Stephens J. C., Reich D. E., Goldstein D. B., Shin H. D., Smith M. W., Carrington M. et al. 1998 Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62, 1507-1515.
89. Takai T. 2002 Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2, 580-592.
90. Tang J., Costello C., Keet I. P., Rivers C., Leblanc S., Karita E. et al. 1999 HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses15, 317-324.
91. Tomiyama H., Miwa K., Shiga H., Moore Y. I., Oka S., Iwamoto A. et al. 1997 Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J. Immunol. 158, 5026-5034.
92. Turner M. W. 1996 Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today17, 532-540.
93. van der Pol W. L., Jansen M. D., Sluiter W. J., van de S. B., Leppersvan de Straat F. G., Kobayashi T. et al. 2003 Evidence for nonrandom distribution of Fcgamma receptor genotype combinations. Immunogenetics55, 240-246.
94. van Rij R. P. Portegies P., Hallaby T., Lange J. M., Visser J., de Roda Husman A. M. et al. 1999 Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J. Infect. Dis. 180, 854-857.
95. Vassalli P. 1992 The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10, 411-452.
96. Warmerdam P. A., van de Winkel J. G., Vlug A., Westerdaal N. A. and Capel P. J. 1991 A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J. Immunol. 147, 1338-1343.
97. Wilson A. G., de V. N., Pociot F., di Giovine F. S., van der Putte L. B. and Duff G. W. 1993 An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 177, 557-560.
98. Winkler C., Modi W., Smith M. W., Nelson G. W., Wu X., Carrington M. et al. 1998 Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, hemophilia growth and development study (HGDS), multicenter AIDS cohort study (MACS), multicenter hemophilia cohort study (MHCS), San Francisco city cohort (SFCC). Science279, 389-393.
99. Wu L., Gerard N. P., Wyatt R., Choe H., Parolin C., Ruffing N. et al. 1996 CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature384, 179-183.
100. Wu L., LaRosa G., Kassam N., Gordon C. J., Heath H., Ruffing N. et al. 1997a Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186, 1373-1381.
101. Wu L., Paxton W. A., Kassam N., Ruffing N., Rottman J. B., Sullivan N. et al. 1997b CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185, 1681-1691.
102. Zimmerman P. A., Buckler-White A., Alkhatib G., Spalding T., Kubofcik J., Combadiere C. et al. 1997 Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3, 23-36.
103. Zinkernagel R. M. 1996 Immunology taught by viruses. Science271, 173-178.